Most trusted source for Tendering Opportunities and Business Intelligence since 2002
Country - Germany
Summary - Conclusion Of A Non-Exclusive Discount Agreement In Accordance With Section 130A Paragraph 8 Sgb V For The Active Ingredient Tocilizumab, Atc L04Ac07 For The Period December 1St, 2023 - November 30Th, 2024 (Plus Extension Option 1X12 Months)
Deadline - Oct 05, 2025
GT reference number - 73405643
Product classification - Pharmaceutical products
Address - Germany
Contact details - 565656565
Tender notice no. - 76454545
GT Ref Id - 73405643
Document Type - Tender Notices
Description - Section 130a paragraph 8 SGB V enables health insurance companies and pharmaceutical companies to conclude framework discount agreements for the medicines to be supplied at the expense of the statutory health insurance companies. With regard to the r elevant legal regulations for the awarding of public contracts, a regular process of active ingredient-related, formal procurement procedures takes place in accordance with the regulations of Part 4 of the GWB by DAK-Gesundheit. For medicinal products to be specified by the bidder in Annex 2 to the contract in relation to the above. Active ingredient, tocilizumab (exclusively pre-filled syringe and pre-filled pen), ATC L04AC07, DAK-Gesundheit int
Gt Ref Id - 73405643
Deadline - Oct 05, 2025
Similar Tenders :
Why Us
3,00,000 +
Users
190 +
Countries Covered
5,00,000 +
Agencies Tracked
50,000 +
Notices Daily
90 Million +
Database